

1 **Impact of Diagnostic Stewardship on Ordering Trends and Pathogen Yield from**
2 **mNGS Studies**

3

4 Running title: Impacts of mNGS Stewardship

5

6 Ryan C. Shean^{1,2,#}, Elizabeth Garrett^{3,#}, James Malleis⁴, Joshua A. Lieberman^{4*},

7 Benjamin T. Bradley^{1,2*}

8

9 ¹Department of Pathology, University of Utah, Salt Lake City, UT

10 ²ARUP Laboratories, Salt Lake City, UT

11 ³Department of Pathology and Laboratory Medicine, The Pennsylvania State University,

12 Hershey, PA

13 ⁴Department of Laboratory Medicine and Pathology, University of Washington, Seattle,

14 WA

15 # These authors contributed equally to this work

16 *Co-corresponding authors, Benjamin T. Bradley, ben.bradley@hsc.utah.edu; Joshua

17 A. Lieberman, joshuaal@uw.edu

18 Keywords: stewardship, mNGS, microbiology, ordering practices, test utilization

19 Background

20 Given the cost and unclear clinical impact of metagenomic next-generation sequencing
21 (mNGS), laboratory stewardship may improve utilization. This study examines mNGS
22 results from two academic medical centers employing different stewardship
23 approaches.

24 Methods

25 80 mNGS orders (54 CSF and 26 plasma) were identified from 2019 to 2021 at the
26 University of Washington (UW), which requires director-level approval for mNGS orders,
27 and the University of Utah (Utah), which does not restrict ordering. The impact of mNGS
28 results and the relationship to traditional microbiology orders were retrospectively
29 evaluated.

30 Results

31 19% (10/54) CSF and 65% (17/26) plasma studies detected at least one organism.
32 Compared to CSF results, plasma results were more frequently clinically significant
33 (23% vs 7%) and led to more novel diagnoses (15% vs 0%). Results affecting antibiotic
34 management were more common for plasma than CSF (32% vs. 2%). Stewardship
35 practices were not associated with statistically significant differences in results or
36 antimicrobial management. The number and cost of traditional microbiology tests at UW
37 was greater than Utah for CSF mNGS testing (UW: 46 tests, \$6237; Utah: 26 tests,
38 \$2812; $p < 0.05$) but similar for plasma mNGS (UW: 31 tests, \$3975; Utah: 21 tests,
39 \$2715; $p = 0.14$). mNGS testing accounted for 30-50% of the total microbiology costs.

40 Conclusions

41 Improving the diagnostic performance of mNGS by stewardship remains challenging
42 due to low positivity rates and difficulties assessing clinical impact. From a fiscal
43 perspective, stewardship efforts should focus on reducing testing in low-yield
44 populations given the high costs of mNGS relative to overall microbiology testing
45 expenditures.

46 Introduction

47 Next-generation sequencing (NGS) is a powerful technology that allows for
48 millions of DNA fragments to be independently and simultaneously sequenced.
49 Metagenomic NGS (mNGS) is the analytical process by which all nucleic acid can be
50 sequenced and classified, permitting complex populations of nucleic acid from many
51 organisms to be analyzed in a single sample. These technologies have emerged as
52 exciting, but expensive tools to diagnose infections from diverse anatomic sites and
53 specimen types, including cerebrospinal fluid (CSF) and plasma.¹⁻⁶ An advantage of
54 mNGS over traditional microbiological approaches is the ability to detect any bacterial,
55 viral, and fungal organism, without explicit inclusion in the provider's differential
56 diagnosis.^{3,7} This stands in contrast to traditional microbiology testing, including culture,
57 serology, and nucleic acid amplification tests, which depends on the provider's
58 differential diagnosis to help select the appropriate tests^{8,9}. Plasma mNGS can also
59 provide a non-invasive alternative to biopsy for the identification of deep infections such
60 as invasive fungal disease or osteomyelitis and occult infections such as culture-
61 negative endocarditis.¹⁰⁻¹²

62 However, the role of mNGS technology in infectious disease diagnostics and its
63 place in the context of traditional microbiology testing is still unclear. As with other
64 approaches, mNGS can identify clinically irrelevant targets such as colonizing or
65 transient organisms. DNA can also persist well after an organism has been cleared;
66 therefore, mNGS results must be interpreted in the context of the patient's clinical
67 presentation.⁶ Recent studies have described variable clinical utility of mNGS results,
68 finding 12-55% of positive results to be clinically actionable^{13,14}. This variable clinical

69 impact is due to the diverse range of patient populations, clinical syndromes, and
70 matrices that can be assessed with this unbiased diagnostic approach.^{10,14–16}
71 Interpretation of the results is further complicated by differences in the analytic
72 techniques and databases used to classify nucleic acid sequences¹⁷.

73 Due to the novelty, cost, limited clinical impact, and difficulty in properly
74 interpreting mNGS results, a variety of stewardship practices have been implemented to
75 improve test utilization¹⁸. Historically, diagnostic stewardship has been used in clinical
76 microbiology testing to counterbalance well-intentioned but misdirected use¹⁹. Some
77 successful implementations of diagnostic stewardship include decision support testing
78 (e.g., hard stops on *Clostridioides difficile* testing on formed stool samples) as well as
79 automated reflex testing to ensure that proper algorithms are correctly followed²⁰. There
80 is a clear need for evidence-based guidance to help inform when mNGS infectious
81 disease testing will improve patient outcomes¹⁹. Currently available data show
82 diagnostic utility largely depends upon the use case in which mNGS is performed^{14,21,22}.
83 To properly inform diagnostic stewardship guidelines, data such as the cost, timing, and
84 context of mNGS ordering relative to traditional microbiology testing is needed.

85 In this retrospective analysis, we examined CSF and plasma mNGS orders in
86 patients across two different multicenter hospital systems, which provide extensive
87 specialty care for cancer, transplant, and trauma patients. We evaluated mNGS assay
88 performance, impact on antibiotic management, and relationship to traditional
89 microbiology testing in terms of timing and cost. We highlight the impact that
90 stewardship may have on these measures to aid laboratories in the establishment of
91 evidence-based guidelines.

92 **Materials and Methods**

93 Ethics Statement

94 This study was approved by the University of Washington (UW) Institutional
95 Review Board Committee (IRB ID STUDY00010777) and University of Utah (Utah)
96 Institutional Review Board (IRB 00151187) as waived research; informed consent was
97 not required.

98 mNGS Testing

99 CSF mNGS was performed by the University of California San Francisco Clinical
100 Microbiology Lab (California); plasma mNGS was performed by Karius (Redwood City,
101 California). Both laboratories are Clinical Laboratory Improvement Amendments (CLIA)-
102 certified. Samples were submitted in accordance with the specimen requirements for
103 each laboratory.

104 Institutional Approval Processes for mNGS

105 At UW, the interdisciplinary Laboratory Formulary Committee sets an annual limit
106 on the number of mNGS send-out tests and instituted an approval process. Briefly,
107 provider requests for CSF and plasma mNGS testing underwent a collaborative review
108 process between clinical microbiology directors and the care team with required input
109 from infectious disease physicians. Considerations for approval included: 1) expected
110 impact to clinical decision making, 2) traditional microbiologic testing results (cultures,
111 serology, and nucleic acid amplification test (NAAT)), 3) clinical suspicion for infectious
112 etiology, and 4) difficulty of obtaining lesional tissue. Extended factors included
113 underlying medical conditions, immunocompromised status, and recent antibiotic

114 exposure. At Utah, laboratory approval for CSF and plasma mNGS was not required
115 prior to test ordering.

116 Data Collection and Analysis

117 Specimens approved for CSF or plasma mNGS testing at UW from July 2019 to
118 March 2021 and ordered at Utah from January 2019 to December 2021 were
119 retrospectively identified through the laboratory information systems (LIS). Patient
120 charts were reviewed to determine the significance and impact of mNGS testing. Any
121 test result in which one or more organisms were detected by the assay were considered
122 a positive mNGS result. Clinically significant results were adjudicated based on review
123 of the medical chart and impression of the clinical team caring for the patient.

124 Organisms known to cause latent infections (e.g. CMV, EBV) or part of the oral or
125 gastrointestinal flora (e.g., coagulase-negative staphylococci, viridians streptococci)
126 were considered clinically insignificant unless otherwise indicated by the medical team
127 or supported by orthogonal clinical testing. Novel pathogens were defined as organisms
128 deemed clinically significant and not observed by orthogonal means prior to mNGS
129 results. Clinical impact was evaluated based on as alterations in antimicrobial treatment
130 (escalation, de-escalation, or change) that specifically considered mNGS results,
131 positive or negative. Additional data were gathered from the LIS regarding patient
132 demographics and traditional microbiology orders placed. For this study's purposes,
133 traditional microbiology orders were considered any test (culture, serology, antigen, or
134 molecular assay) ordered to assist in the clinical diagnosis excluding mNGS.

135 Surveillance and routine screening studies were excluded. Testing turn-around time

136 (TAT) was calculated from the time the specimen was accessioned to the time the result
137 was received from the performing lab.

138 The billing charges associated with infectious disease testing for patients in this
139 study were evaluated using the hospital fee schedule. In order to standardize cost
140 estimates across both health systems, the UW hospital chargemaster from November
141 2020 was used for both UW and Utah patients²³. For Utah patients who received testing
142 not available on the UW chargemaster, estimated cost of microbiology testing was
143 obtained using the ARUP cost estimator tool
144 (<https://www.aruplab.com/testing/resources/calculator>). Costs between the UW
145 chargemaster and the ARUP cost estimator tool were generally very similar for tests
146 offered by both institutions which also matched closely with the Medicare
147 reimbursement schedule. Only microbiological diagnostic costs from the hospitalization
148 during which mNGS was ordered were included in the analysis, except for one patient
149 who had two hospitalizations 9 days apart for the same clinical syndrome and has tests
150 from both stays included.

151 Data was analyzed in R (v4.2). Statistical tests performed included Pearson's
152 Chi-squared test with Yates' continuity correction and Welch's two sample t-tests.
153 Statistical significance was set at a threshold of $p < 0.05$.

154

155 **Results**

156 Patient Demographics and mNGS Results

157 During the study period, a total of 80 mNGS tests met inclusion criteria, 28 from
158 the UW hospital system and 52 from the Utah hospital system (Table 1). For the UW

159 cohort, mNGS testing was rejected in 12 instances. Reasons included alternative
160 testing methods available in-house (n=5), low concern for an infectious agent (n=3), and
161 a suspected pathogen already identified (n=2). Male and female individuals were
162 equally represented in both CSF mNGS cohorts; however, a higher proportion of males
163 received plasma mNGS studies (81% male vs 19% female). The plasma mNGS cohort
164 included a greater number of immunocompromised individuals relative to the CSF
165 mNGS cohort (77% vs 39%). Excluding the Utah CSF mNGS group, antibiotics were
166 administered to over half of the individuals in each cohort prior to mNGS specimen
167 collection and in 70% of those with a positive mNGS result. At least one individual in
168 each cohort received mNGS testing as an outpatient.

169 Clinical indications for CSF mNGS testing were limited to individuals presenting
170 with neurologic conditions which included clinical features of meningitis or encephalitis,
171 radiologically evident lesions or vasculitis, and sub-acute cognitive impairment. Plasma
172 mNGS was ordered for a wider range of indications including endovascular disease
173 such as culture negative endocarditis (50%, 13/26), neurologic dysfunction (19%, 5/26),
174 pulmonary lesions with negative microbiologic culture or contraindications for lesion
175 biopsy (15%, 4/26), fever of unknown origin (12%, 3/26), and liver abscess (4%, 1/26).

176 At least one organism was detected in 19% (10/54) of CSF specimens and 65%
177 (17/26) of plasma specimens. Overall, plasma mNGS results were more likely to identify
178 clinically significant pathogens compared to CSF (23% vs 7%). Plasma mNGS was also
179 more likely to identify novel pathogens compared to CSF mNGS (15% vs 0%). While
180 differences between study site results did not reach statistical significance, clinically
181 significant organisms from plasma were observed at twice the frequency in the UW

182 cohort (28%, n= 5) as compared to the Utah cohort (13%, n= 1). Similarly, all novel
183 mNGS results (n=4) occurred in the UW plasma CSF group. Prior antibiotic use was not
184 associated with a decreased likelihood of detecting a clinically significant pathogen.

185 Alterations in antimicrobial therapy were infrequent within the CSF mNGS cohort
186 with only one result leading to a change in therapy. Antibiotic management changes
187 were more frequent in the plasma mNGS cohort with 31% (8/26) of results leading to a
188 change in management. Plasma mNGS results also demonstrated a similar impact on
189 management between Utah and UW (25% and 33%). In 44% (4/9) of cases where
190 mNGS results affected antibiotic management, the change was made following a
191 negative result (n=1) or identification of a non-significant pathogen (n=3) (Supplemental
192 Table 1).

193 Ordering Practices and Costs for Conventional Microbiology Testing

194 A common criticism of mNGS is the high cost of a single test. The average cost
195 of plasma mNGS and CSF mNGS in this study was \$2000 and \$2900, respectively. We
196 compared the volume and associated costs of other microbiology testing ordered for the
197 same clinical syndrome which led to use of mNGS (Figure 1). A significant difference
198 was seen between study sites for CSF mNGS testing (UW: 46 tests, \$6237; Utah: 26
199 tests, \$2812; $p < 0.05$) but not for plasma mNGS testing (UW: 31 tests, \$3975; Utah: 21
200 tests, \$2715; $p = 0.14$) (Table 2, Figure 2A). The greater number of total tests in the UW
201 CSF mNGS group was due to a comparatively higher number of tests ordered prior to
202 mNGS testing (UW: 40; Utah: 20, $p < 0.05$). In the period following CSF mNGS, testing
203 volumes were similar between sites (UW: 6; Utah: 6, $p = 0.89$). In relative terms, mNGS
204 accounted for 30-50% of the total microbiology testing costs regardless of test or

205 stewardship practice (Figure 2B). While CSF mNGS was ordered earlier for Utah
206 patients than for UW patients (4.5 vs 14 days), the majority were discharged by the time
207 results were available whereas UW patients were more likely to remain inpatients (52%
208 vs 10%). For plasma mNGS, 0% (0/8) of Utah patients and 6% (1/18) of UW patients
209 were discharged at time of mNGS result.

210 Traditional microbiology orders varied relative to the type of mNGS test (CSF vs.
211 plasma) and timing (pre vs. post-mNGS) (Table 3). For individuals undergoing CSF
212 mNGS, the two most common traditional microbiology tests were CSF culture and blood
213 culture. Tests that were relatively more common after CSF mNGS ordering included
214 tissue bacterial cultures and tissue fungal cultures. For plasma mNGS orders, the most
215 common tests overall were bacterial and fungal cultures from blood. As was observed in
216 the CSF mNGS cohort, tests from invasively collected specimens such as tissue
217 bacterial cultures and tissue fungal cultures were ordered more frequently following
218 plasma mNGS orders.

219

220 **Discussion**

221 The introduction of mNGS into clinical microbiology represents an exciting
222 prospect for the diagnosis of infectious disease. However, the role of this technology
223 remains a matter of discussion, as is reflected by the variable performance of mNGS in
224 clinical practice.^{21,24} In this study we found that 19% (10/54) of CSF results and 65%
225 (17/26) of plasma results were positive but only 2% (1/54) of CSF results and 31%
226 (8/26) of plasma results led to a change in antimicrobial therapy. Stewardship was not
227 associated with a statistically higher rate of results which changed management. These

228 results are similar to other studies which have demonstrated a low return of clinically
229 actionable results from mNGS.^{10,12,14}

230 While improving diagnostic yields may prove challenging, a more attainable goal
231 for stewardship programs can be the reduction of low-yield testing. The advantages of
232 stewardship are best highlighted when comparing CSF mNGS patient populations
233 between Utah and UW. At Utah, where ordering was not regulated, 68% (30/44) of
234 patients were either tested as outpatients or discharged by the time results were
235 available. This stands in contrast to UW where only 20% (2/10) met these criteria. It
236 could be argued that one potential benefit of the policy at Utah was that mNGS was
237 performed earlier (4 vs. 14 days) and with fewer traditional microbiology studies (26 vs.
238 46) relative to UW, thus increasing the likelihood of yielding novel or actionable results.
239 However, within the Utah cohort no novel diagnoses were made and antibiotic
240 management was only affected in one case following a negative result.

241 The CSF mNGS test was developed to detect esoteric and infrequent pathogens
242 in patients with a high likelihood of unexplained infectious meningitis/encephalitis.
243 However, in a significant number of cases the assay was used as part of a 'rule-out'
244 approach prior to initiation of biologics for autoimmune encephalitis. Limiting these
245 orders is critically important as data suggest that CSF mNGS may not achieve the
246 sensitivity sufficient to rule-out infection as compared to traditional microbiological
247 diagnostics.^{1,14} In our data, we also observed a high rate of non-clinically significant
248 organisms identified from plasma mNGS. Reducing the risk of potential false positive
249 and false negative results is best achieved by limiting mNGS studies to populations with
250 a high pre-test probability of infection.^{12,14}

251 Interestingly, we observed a significantly longer TAT for plasma mNGS at UW as
252 compared to Utah. We hypothesize that specimens were collected and then held while
253 the expert committee reviewed the case and/or awaited results from pending,
254 conventional microbiology tests. If correct, the additional time due to stewardship
255 activities may account for the longer TAT at UW.

256 This study provides a starting point for analyzing the impact of stewardship on
257 the overall cost of microbiology testing in patients receiving mNGS. While the total
258 microbiology testing costs were lower per individual in the unsupervised setting at Utah,
259 this fails to account for cost saving generated by avoiding unnecessary mNGS studies
260 in low-yield patients. For this reason, costs saving should be assessed at the systems
261 level and not the patient level. Another important finding of our study is that the cost of a
262 single mNGS assay is similar to the total cost of all other microbiology tests ordered.
263 Therefore, requiring more traditional microbiology testing prior to mNGS ordering is
264 likely a cost-effective policy. However, this approach risks potential delays in diagnosis
265 if negative cultures or finalized results are required prior to mNGS approval. Specific
266 clinical use cases for mNGS and pre-requisite traditional microbiology studies should be
267 established in a multidisciplinary process prior to testing.

268 Several limitations exist in this study; first is the retrospective nature of the data
269 collected and the post-hoc assessment of mNGS results on antibiotic management. We
270 attempted to use a narrow, but well-defined criteria that could be supported by the
271 clinical record. However, mNGS results may be assessed for much wider clinical
272 impacts and the impact of a negative result may be difficult to determine from the
273 clinical record.¹⁴ Specifically, assessing the clinical impact of a negative CSF result from

274 a patient with a pre-existing low probability of infection remains challenging and will
275 require studies constructed to examine this question. While this study provides cost
276 estimates from two different hospital systems, it is possible these estimates may not be
277 widely generalizable between hospital systems. Individual nuances including clinical
278 service leadership and physician ordering practices hinder direct comparisons to this
279 study. It is important for any system considering mNGS stewardship to realize policies
280 will need to be built on an individual basis and tailored to the patient population.

281 This study provides several lessons for developing mNGS stewardship policies.
282 First, clinical performance may not be the primary endpoint to evaluate the success of
283 mNGS stewardship as the likelihood of positive results or changes in management are
284 low regardless of approach. Instead, programs should focus on reducing testing in low-
285 value situations, specifically for patients who will be discharged prior to the results
286 becoming available and in patients for whom “rule-out” testing is requested. This latter
287 situation was commonly observed when patients underwent CSF mNGS studies prior to
288 initiation of immunosuppressants. Examining the financial impacts of mNGS
289 stewardship should be examined in aggregate, and costs savings associated with
290 preventing low-yield mNGS testing should be noted. The threshold for suggesting
291 additional pathogen-directed testing prior to mNGS should be low given mNGS may
292 account for 30-50% of total testing costs while marginally improving detection of novel
293 pathogens. Finally, decisions for mNGS send-out testing approval should be made
294 expeditiously to prevent testing delays.

295

296 References

- 297 (1) Blauwkamp, T. A.; Thair, S.; Rosen, M. J.; Blair, L.; Lindner, M. S.; Vilfan, I. D.;
298 Kawli, T.; Christians, F. C.; Venkatasubrahmanyam, S.; Wall, G. D.; Cheung, A.;
299 Rogers, Z. N.; Meshulam-Simon, G.; Huijse, L.; Balakrishnan, S.; Quinn, J. V.;
300 Hollemon, D.; Hong, D. K.; Vaughn, M. L.; Kertesz, M.; Bercovici, S.; Wilber, J. C.;
301 Yang, S. Analytical and Clinical Validation of a Microbial Cell-Free DNA
302 Sequencing Test for Infectious Disease. *Nat. Microbiol.* **2019**, *4* (4), 663–674.
303 <https://doi.org/10.1038/s41564-018-0349-6>.
- 304 (2) Miller, S.; Naccache, S. N.; Samayoa, E.; Messacar, K.; Arevalo, S.; Federman, S.;
305 Stryke, D.; Pham, E.; Fung, B.; Bolosky, W. J.; Ingebrigtsen, D.; Lorizio, W.; Paff,
306 S. M.; Leake, J. A.; Pesano, R.; DeBiasi, R.; Dominguez, S.; Chiu, C. Y. Laboratory
307 Validation of a Clinical Metagenomic Sequencing Assay for Pathogen Detection in
308 Cerebrospinal Fluid. *Genome Res.* **2019**. <https://doi.org/10.1101/gr.238170.118>.
- 309 (3) Chiu, C. Y.; Miller, S. A. Clinical Metagenomics. *Nat. Rev. Genet.* **2019**, *20* (6),
310 341–355. <https://doi.org/10.1038/s41576-019-0113-7>.
- 311 (4) Zhou, Y.; Wylie, K. M.; El Feghaly, R. E.; Mihindukulasuriya, K. A.; Elward, A.;
312 Haslam, D. B.; Storch, G. A.; Weinstock, G. M. Metagenomic Approach for
313 Identification of the Pathogens Associated with Diarrhea in Stool Specimens. *J.*
314 *Clin. Microbiol.* **2016**, *54* (2), 368–375. <https://doi.org/10.1128/JCM.01965-15>.
- 315 (5) Huang, J.; Jiang, E.; Yang, D.; Wei, J.; Zhao, M.; Feng, J.; Cao, J. Metagenomic
316 Next-Generation Sequencing versus Traditional Pathogen Detection in the
317 Diagnosis of Peripheral Pulmonary Infectious Lesions. *Infect. Drug Resist.* **2020**,
318 *13*, 567–576. <https://doi.org/10.2147/IDR.S235182>.
- 319 (6) Greninger, A. L.; Naccache, S. N. Metagenomics to Assist in the Diagnosis of
320 Bloodstream Infection. *J. Appl. Lab. Med.* **2019**, *3* (4), 643–653.
321 <https://doi.org/10.1373/jalm.2018.026120>.
- 322 (7) Farnaes, L.; Wilke, J.; Ryan Loker, K.; Bradley, J. S.; Cannavino, C. R.; Hong, D.
323 K.; Pong, A.; Foley, J.; Coufal, N. G. Community-Acquired Pneumonia in Children:
324 Cell-Free Plasma Sequencing for Diagnosis and Management. *Diagn. Microbiol.*
325 *Infect. Dis.* **2019**, *94* (2), 188–191.
326 <https://doi.org/10.1016/j.diagmicrobio.2018.12.016>.
- 327 (8) Rakeman, J. L.; Bui, U.; Lafe, K.; Chen, Y.-C.; Honeycutt, R. J.; Cookson, B. T.
328 Multilocus DNA Sequence Comparisons Rapidly Identify Pathogenic Molds. *J. Clin.*
329 *Microbiol.* **2005**, *43* (7), 3324–3333. [https://doi.org/10.1128/JCM.43.7.3324-](https://doi.org/10.1128/JCM.43.7.3324-3333.2005)
330 [3333.2005](https://doi.org/10.1128/JCM.43.7.3324-3333.2005).
- 331 (9) Salipante, S. J.; Sengupta, D. J.; Rosenthal, C.; Costa, G.; Spangler, J.; Sims, E.
332 H.; Jacobs, M. A.; Miller, S. I.; Hoogestraat, D. R.; Cookson, B. T.; McCoy, C.;
333 Matsen, F. A.; Shendure, J.; Lee, C. C.; Harkins, T. T.; Hoffman, N. G. Rapid 16S
334 rRNA Next-Generation Sequencing of Polymicrobial Clinical Samples for Diagnosis
335 of Complex Bacterial Infections. *PLoS One* **2013**, *8* (5), e65226.
336 <https://doi.org/10.1371/journal.pone.0065226>.
- 337 (10) Lee, R. A.; Al Dhaheri, F.; Pollock, N. R.; Sharma, T. S. Assessment of the Clinical
338 Utility of Plasma Metagenomic Next-Generation Sequencing in a Pediatric Hospital
339 Population. *J. Clin. Microbiol.* **2020**, *58* (7). <https://doi.org/10.1128/JCM.00419-20>.

- 340 (11) Hong, D. K.; Blauwkamp, T. A.; Kertesz, M.; Bercovici, S.; Truong, C.; Banaei, N.
341 Liquid Biopsy for Infectious Diseases: Sequencing of Cell-Free Plasma to Detect
342 Pathogen DNA in Patients with Invasive Fungal Disease. *Diagn. Microbiol. Infect.*
343 *Dis.* **2018**, *92* (3), 210–213. <https://doi.org/10.1016/j.diagmicrobio.2018.06.009>.
- 344 (12) Rossoff, J.; Chaudhury, S.; Soneji, M.; Patel, S. J.; Kwon, S.; Armstrong, A.; Muller,
345 W. J. Noninvasive Diagnosis of Infection Using Plasma Next-Generation
346 Sequencing: A Single-Center Experience. *Open Forum Infect. Dis.* **2019**, *6*
347 (ofz327). <https://doi.org/10.1093/ofid/ofz327>.
- 348 (13) Wu, J.; Song, W.; Yan, H.; Luo, C.; Hu, W.; Xie, L.; Shen, N.; Cao, Q.; Mo, X.; An,
349 K.; Tao, Y. Metagenomic Next-Generation Sequencing in Detecting Pathogens in
350 Pediatric Oncology Patients with Suspected Bloodstream Infections. *Pediatr. Res.*
351 **2024**, *95* (3), 843–851. <https://doi.org/10.1038/s41390-023-02776-y>.
- 352 (14) Hogan, C. A.; Yang, S.; Garner, O. B.; Green, D. A.; Gomez, C. A.; Dien Bard, J.;
353 Pinsky, B. A.; Banaei, N. Clinical Impact of Metagenomic Next-Generation
354 Sequencing of Plasma Cell-Free DNA for the Diagnosis of Infectious Diseases: A
355 Multicenter Retrospective Cohort Study. *Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc.*
356 *Am.* **2021**, *72* (2), 239–245. <https://doi.org/10.1093/cid/ciaa035>.
- 357 (15) Lieberman, J. A.; Naureckas Li, C.; Lamb, G. S.; Kane, D. A.; Stewart, M. K.;
358 Mamedov, R. A.; Cookson, B. T.; Salipante, S. J. Case Report: Comparison of
359 Plasma Metagenomics to Bacterial PCR in a Case of Prosthetic Valve
360 Endocarditis. *Front. Pediatr.* **2020**, *8*, 575674.
361 <https://doi.org/10.3389/fped.2020.575674>.
- 362 (16) Wilson, M. R.; Sample, H. A.; Zorn, K. C.; Arevalo, S.; Yu, G.; Neuhaus, J.;
363 Federman, S.; Stryke, D.; Briggs, B.; Langelier, C.; Berger, A.; Douglas, V.;
364 Josephson, S. A.; Chow, F. C.; Fulton, B. D.; DeRisi, J. L.; Gelfand, J. M.;
365 Naccache, S. N.; Bender, J.; Dien Bard, J.; Murkey, J.; Carlson, M.; Vespa, P. M.;
366 Vijayan, T.; Allyn, P. R.; Campeau, S.; Humphries, R. M.; Klausner, J. D.; Ganzon,
367 C. D.; Memar, F.; Ocampo, N. A.; Zimmermann, L. L.; Cohen, S. H.; Polage, C. R.;
368 DeBiasi, R. L.; Haller, B.; Dallas, R.; Maron, G.; Hayden, R.; Messacar, K.;
369 Dominguez, S. R.; Miller, S.; Chiu, C. Y. Clinical Metagenomic Sequencing for
370 Diagnosis of Meningitis and Encephalitis. *N. Engl. J. Med.* **2019**, *380* (24), 2327–
371 2340. <https://doi.org/10.1056/NEJMoa1803396>.
- 372 (17) Batool, M.; Galloway-Peña, J. Clinical Metagenomics—Challenges and Future
373 Prospects. *Front. Microbiol.* **2023**, *14*, 1186424.
374 <https://doi.org/10.3389/fmicb.2023.1186424>.
- 375 (18) Goggin, K. P.; Fox, T. G.; Jaggi, P.; Shane, A. L.; Gonzalez, M. D. Impact of a New
376 Diagnostic Stewardship Team on Utilization and Interpretation of a Microbial Cell-
377 Free DNA Detection Test. *J. Pediatr. Infect. Dis. Soc.* **2023**, *12* (Supplement_1),
378 S24. <https://doi.org/10.1093/jpids/piad070.049>.
- 379 (19) Gaston, D. C.; Chiang, A. D.; Dee, K.; Dulek, D.; Banerjee, R.; Humphries, R. M.
380 Diagnostic Stewardship for Next-Generation Sequencing Assays in Clinical
381 Microbiology: An Appeal for Thoughtful Collaboration. *Clin. Lab. Med.* **2024**, *44* (1),
382 63–73. <https://doi.org/10.1016/j.cll.2023.10.002>.
- 383 (20) Morjaria, S.; Chapin, K. C. Who to Test, When, and for What: Why Diagnostic
384 Stewardship in Infectious Diseases Matters. *J. Mol. Diagn.* **2020**, *22* (9), 1109–
385 1113. <https://doi.org/10.1016/j.jmoldx.2020.06.012>.

- 386 (21) Miller, S.; Chiu, C.; Rodino, K. G.; Miller, M. B. Point-Counterpoint: Should We Be
387 Performing Metagenomic Next-Generation Sequencing for Infectious Disease
388 Diagnosis in the Clinical Laboratory? *J. Clin. Microbiol.* **2019**, *58* (3), e01739-19,
389 /jcm/58/3/JCM.01739-19.atom. <https://doi.org/10.1128/JCM.01739-19>.
- 390 (22) Heldman, M. R.; Ahmed, A. A.; Liu, W.; Vo, A.; Keane-Candib, J.; Stevens-Ayers,
391 T.; Boeckh, M.; Blauwkamp, T. A.; Fisher, C. E.; Hill, J. A. Serial Quantitation of
392 Plasma Microbial Cell-Free DNA Before and After Diagnosis of Pulmonary Invasive
393 Mold Infections After Hematopoietic Cell Transplant. *J. Infect. Dis.* **2024**, *229* (2),
394 576–587. <https://doi.org/10.1093/infdis/jiad255>.
- 395 (23) Batty, M.; Ippolito, B. Mystery Of The Chargemaster: Examining The Role Of
396 Hospital List Prices In What Patients Actually Pay. *Health Aff. Proj. Hope* **2017**, *36*
397 (4), 689–696. <https://doi.org/10.1377/hlthaff.2016.0986>.
- 398 (24) Babady, N. E. Clinical Metagenomics for Bloodstream Infections: Is the Juice
399 Worth the Squeeze? *Clin. Infect. Dis.* **2021**, *72* (2), 246–248.
400 <https://doi.org/10.1093/cid/ciaa041>.
- 401

402

403 **Table 1 - Demographic and Clinical Information for Individuals Receiving mNGS**

	CSF			Plasma		
	Utah	UW	Total	Utah	UW	Total
Individuals	44	10	54	8	18	26
Median Age (IQR)	45 (33-46)	47 (34-51)	45 (35-64)	52 (41-49)	52 (41-57)	53 (41-62)
Sex (n, [%])						
Male	18 (41%)	4 (40%)	22 (41%)	8 (100%)	13 (72%)	21 (81%)
Female	26 (59%)	6 (60%)	32 (59%)	0 (0%)	5 (28%)	5 (19%)
Clinical Information (n, [%])						
Immunosuppressed	15 (34%)	4 (40%)	21 (39%)	7 (88%)	13 (72%)	20 (77%)
Received antibiotics	12 (27%)	8 (80%)	20 (37%)	5 (63%)	17 (94%)	22 (85%)
Outpatient	7 (16%)	1 (10%)	8 (15%)	1 (13%)	2 (11%)	3 (12%)
Clinical Indication (n, [%])						
Neurologic	44 (100%)	10 (100%)	54 (100%)	4 (50%)	1 (6%)	5 (19%)
Endovascular	0 (0%)	0 (0%)	0 (0%)	2 (25%)	11 (61%)	13 (50%)
Pulmonary	0 (0%)	0 (0%)	0 (0%)	1 (13%)	3 (17%)	4 (15%)
FUO	0 (0%)	0 (0%)	0 (0%)	1 (13%)	2 (11%)	3 (12%)
Results (n, [%])						
Positive mNGS results	10 (23%)	0 (0%)	10 (19%)	6 (75%)	11 (61%)	17 (65%)
--Clinically significant	4 (9%)	0 (0%)	4 (7%)	1 (13%)	5 (28%)	6 (23%)
--Novel	0 (0%)	0 (0%)	0 (0%)	0 (0%)	4 (22%)	4 (15%)
Change in antibiotic management	1 (2%)	0 (0%)	1 (2%)	2 (25%)	6 (33%)	8 (31%)

404

405 **Table 2** - Traditional Microbiology Test Volume and Cost for Individuals Receiving mNGS


	CSF			Plasma		
	Utah	UW	p-value	Utah	UW	p-value
Micro tests ordered (mean, [SD])						
Total	26 (18)	46 (18)	0.01	21 (8)	31 (25)	0.14
Pre-mNGS	20 (12)	40 (15)	0.005	16 (8)	23 (13)	0.15
Post-mNGS	6 (12)	6 (4)	0.89	5 (6)	9 (19)	0.43
Cost (mean, [SD])						
Total	2812 (2007)	6237 (2923)	0.008	2715 (1223)	3975 (524)	0.37
Pre-mNGS	2147 (1392)	5123 (2160)	0.003	2125 (1096)	2399 (1965)	0.67
Post-mNGS	665 (1171)	811 (878)	0.67	589 (804)	1575 (4552)	0.41
mNGS ordering						
Hospital Day mNGS ordered (range)	4.5 (0-21)	14 (2-80)	0.03	12 (7-24)	6.5 (2-24)	0.38
Median TAT, days (range)	14 (9-26)	14 (6-21)	0.65	1 (1-4)	3 (2-7)	0.05
Discharged at time of result, n	23	1	0.03	0	1	0.79

406

407 **Table 3 - Most Common Traditional Microbiology Tests Ordered for Individuals Receiving mNGS**


CSF					
Pre-mNGS		Post-mNGS		Total	
Test	Number	Test	Number	Test	Number
CSF culture	81	AFB culture	17	CSF culture	92
Blood culture	64	Blood culture	17	Blood culture	81
HSV PCR	55	Tissue culture	15	AFB culture with stain	68
AFB culture	51	CSF culture	11	HSV PCR	63
VZV EIA	48	CMV PCR	10	Cryptococcal Antigen	53
Cryptococcal Antigen	47	Tissue fungal culture	10	VZV EIA	51
CSF multiplex PCR	45	Bacterial culture, body fluid	9	CSF multiplex PCR	48
CSF fungal culture	40	CSF culture, anaerobic	8	CMV PCR	44
VZV PCR	38	HSV PCR	8	CSF fungal culture	44
CMV PCR	34	Coccidioides Ab compfix	8	VZV PCR	44
Plasma					
Pre-mNGS		Post-mNGS		Total	
Test	Number	Test	Number	Test	Number
Blood culture	128	Blood culture	20	Blood culture	148
Blood fungal culture	27	Broad-range fungal PCR	15	Blood fungal culture	28
AFB culture	13	M. tb complex PCR	14	AFB culture	25
Aspergillus galactomanin EIA	12	Broad-range bacterial PCR	14	Broad-range fungal PCR	22
Urine Culture	11	AFB culture	12	Broad-range bacterial PCR	20
Brucella Ab screen, agglutination	9	Tissue culture	12	Tissue culture	19
Bartonella Ab panel	9	NTM PCR	12	M. tb complex PCR	16
Q fever Ab, IgG and IgM	9	Tissue fungal with direct exam	6	NTM PCR	14
EBV quant PCR	8	Wound culture, anaerobic	4	Urine Culture	12
Nocardia Culture	7	Brucella Ab screen, agglutination	3	Aspergillus galactomanan EIA	12

408



411 **Figure 1.** - Total and Relative Volumes of Traditional Microbiology Test Orders for Patients
412 Receiving mNGS

413 A) Traditional microbiology testing volumes for patients undergoing CSF or plasma mNGS
414 studies. Results separated by study site and test. Box and whisker plot represents mean, IQR,
415 and 95th percentile. B) Average proportion of total traditional microbiology tests ordered before
416 and after plasma or CSF mNGS at Utah and UW. The mNGS order represents the relative size
417 of a single test order.



420 **Figure 2.** - Total and Relative Cost of Traditional Microbiology Test Orders for Patients
421 Receiving mNGS

422 A) Traditional microbiology testing costs for patients undergoing CSF or plasma mNGS studies.
423 Results separated by study site and test. Box and whisker plot represents mean, IQR, and 95th
424 percentile. B) Cost of traditional and mNGS orders relative to the overall microbiology testing
425 expenditure.